September 15th 2023
Moderna reported at its annual R&D day that its flu vaccine has met primary phase 3 endpoints and that phase 1/2 data show higher HIA titers vs Fluzone HD.
Live Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease – Individualizing Vaccine Recommendations in Adolescent Populations
10/22/2023
Register Now!
Burst CME: Selecting an Appropriate Influenza Vaccine for Adults 65 Years and Older
View More
State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
View More
Community Practice Connections™: State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
Understanding RSV: What You Need to Know to Prevent and Treat Respiratory Syncytial Virus in Your Patients
View More
Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines
View More
Medical Crossfire®: Which Patients with Hematologic Malignancies are at Risk for Secondary Immunodeficiency (SID)… and How Can We Leverage Evidence to Improve Their Outcomes?
View More